/ Print /

  • linkedin
  • Increase Font
  • Sharebar

    Pediatric drug market poised for growth


    The global market for pediatric medicines registers a compound annual growth rate of 3.8% and is expected to reach more than $100 billion by 2019, according to a 2014 BCC Research report.  

    That’s due to the industry designing and implementing more trials in the pediatric population, as well as an increased focus on orphan drug diseases affecting children, according to the report.

    Also aiding in the development of pediatric medications are two laws: the Pediatric Research Equity Act (PREA) and the Best Pharmaceuticals for Children Act (BPCA), which were permanently reauthorized in 2012.

    PREA requires sponsors of certain new drug applications to study their products in children. BPCA provides incentives for sponsors to voluntarily conduct studies in pediatrics by granting them an additional six months of market exclusivity. An update of PREA, the Research to Accelerate Cures and Equity (RACE) for Children Act, recently passed the U.S. Senate. This law contains explicit guidance for cancer drug development that could expand the number of pediatric cancer drug treatments.

    New pediatric drugs

    Several new medications have recently been approved for use in the pediatric population. Mort Goldman, PharmD, FCCP, BCPS, senior consultant, Pharmacy Consulting International, lists some of these new drugs and their anticipated costs:

    • Brineura (cerliponase alfa). An enzyme replacement therapy indicated to slow loss of ambulation in pediatric patients with Batten disease. The annual cost per patient to treat this disease with Brineura could be 1.5 million.
    • Bavencio (avelumab). Immunotherapy for the treatment of patients aged 12 years and older with metastatic Merkel cell carcinoma. Annual cost per patient may total up to $90,000.
    • Emflaza (deflazacort). An oral corticosteroid indicated to treat patients aged 5 years and older with Duchenne muscular dystrophy. Annual cost per patient of up to $100,000.
    • Defitelio (defibrotide sodium). An anticoagulant for the treatment of adults and children who develop hepatic veno-occlusive disease with additional abnormalities following hematopoietic stem cell transplantation. One 21-day treatment course may cost up to $85,000.

    Next: Expanded indications

    1 Comment

    You must be signed in to leave a comment. Registering is fast and free!

    All comments must follow the ModernMedicine Network community rules and terms of use, and will be moderated. ModernMedicine reserves the right to use the comments we receive, in whole or in part,in any medium. See also the Terms of Use, Privacy Policy and Community FAQ.

    • [email protected]
      I Was Diagnosed With Herpes 1 Year Ago I lived In Pain, With The Knowledge That I Wasn't Going To Ever Be Well Again I Contacted So Many Herbal Doctors And Also Visited Hospitals All In Vain My Condition Never Got Better I Was Determined To Get Cured, So One Day As I Was Browsing True The Internet I Saw A Past About This Particular Woman (Stephanie Wilson) Posted On How Dr Ojo Saved Her From The Virus With Herbal Medicine I Decided To Contact Dr Ojo On His Email Address [email protected] We Spoke On The Issue I Told Him All That I Went Through And He Told Me Not To Worry That Everything Will Be Fine Again So He Prepared The Medicine And Sent It To Me And Told Me On How To Use It,After 2 Weeks Of Usage I Went To See Doctor For Test ,Then The Result Was Negative,Am The Happiest Woman On Earth Today..Thanks To Dr Ojo God Bless You, You Can Also Reach Him With This Details; Email; [email protected] Whats_App number Or Call +2348145643630 He also cure these virus {1}HIV And AIDS {2}Diabetes {3}Epilepsy {4} Blood Cancer {5} HPV {6} ALS {7} Hepatitis {8} Vitiligo

    Follow Us On Twitter

    Find us on Facebook

    Latest Tweets Follow